Vitamin A slows down cell turnover and reduces sebum production and reduces bacteria formation in skin too
Skipping doses, doubling doses, changing syringe units, copying another patients instructions, or using online dose charts can create confusion and risk
Semaglutide (GLP-1 agonist) shows efficacy for weight loss and cardiovascular risk reduction, with clinical trials demonstrating 1015% body weight reduction in select populations
Key Market Trends to Watch Through 2035 Several trends are expected to shape the future of the GLP-1 industry: Rapid growth of oral GLP-1 drugs Expansion into cardiovascular and neurological indications Development of triple-agonist therapies Increased use of AI-driven drug discovery Greater telehealth integration Growth of biosimilars in emerging markets Employer-sponsored weight management programs Personalized obesity treatment approaches Together, these trends could redefine the future of chronic disease management
With 800+ senior leaders and 200 speakers, it explores how tech, policy and capital drive innovation to adoption, plus curated networking and insights